biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression a randomized controlled trial生物效应的附加二十碳五烯酸补充在糖尿病和抑郁症共存一个随机对照试验.pdf

Biological Effects of Add-On Eicosapentaenoic Acid Supplementation in Diabetes Mellitus and Co-Morbid Depression: A Randomized Controlled Trial 1 1 2 3 1 Roel J. T. Mocking *, Johanna Assies , Mariska Bot , Eugene H. J. M. Jansen , Aart H. Schene , Franc¸ois Pouwer2 1 Program for Mood Disorders, Department of Psychiatry, Amsterdam Medical Center, Amsterdam, The Netherlands, 2 CoRPS — Center of Research on Psychology in Somatic diseases, Department of Medical Psychology and Neuropsychology, Tilburg University, Tilburg, The Netherlands, 3 National Institute for Public Health and the Environment, Laboratory for Health Protection Research, Bilthoven, The Netherlands Abstract Background: Eicosapentaenoic acid (EPA) may reduce increased risks for (cardiovascular) morbidity and mortality in patients with diabetes mellitus (DM) and comorbid major depressive depression (MDD). Yet, effects of EPA-supplementation on biological risk factors for adverse outcomes have not been studied in DM-patients with MDD. Methods: We performed a randomized, double-blind trial (n = 25) comparing add-on ethyl-EPA-supplementation to placebo on (I) oxidative stress, (II) inflammatory, (III) hypothalamic-pituitary-adrenal (HPA)-axis, (IV) one-carbon-cycle, (V) fatty acid metabolism and (VI) lipoprotein parameters during 12-weeks’ follow-up. Results: Besides increases in supplemented a-tocopherol [estimate (95% CI); 3.62 (1.14–6.11) mmol/l; p = 0.006] and plasma and erythrocyte EPA, the intervention did not influence other oxidative stress, inflammatory or one-carbon-cycle parameters compared to placebo. HPA-axis reactivity significantly decreased in the EPA-group (N = 12) [AUCi: 2121.93 (2240.20–23.47) min 6nmol/l; p = 0.045], not in the placebo-group (N = 12). Furth